Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxelis booster study in healthy children previously primed with Vaxelis or Hexyon
2021-004053-23Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of DTaP-IPV-Hep B-PRP-T vaccine in Vaccine-preventable disease (VPD) (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants with solicited injection-site adverse events from Day 1 through Day 5 postvaccination. Started Dec 2021; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
Vaccine-preventable disease (VPD)
Beyond the preview
Go deeper on 2021-004053-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004053-23.